05:58 AM EDT, 10/14/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) reported Q3 revenue Tuesday of $206 million, up from $135 million a year earlier.

Two analysts polled by FactSet expected $205.1 million.

For 2025, the company now expects revenue of $800 million to $820 million, up from its previous outlook range of $770 million to $800 million. Analysts polled by FactSet expect $794.7 million.

Telix shares were up 3.7% in recent premarket activity.